Innovation Pharmaceuticals Inc (IPIX)

[Ultimate01]

Team, if you have HBO please watch: "Vice Special Report: Killing Cancer"

*** the focus is on targeted T cells for Acute Lymphoblastic Leukemia (ALL)

*** 2 things that we should note

A. The Dr Studying the treatment ran out of money so he published anyway in the NYT with only 4 patients in the study to date. He was able to raise money and continue.

B. More importantly, the doctor feels the TX will go to market in 2016.

I feel both of these things are important to highlight because if your product works finding research money isn't that difficult. Second, this is only a 4 patient study that had impressive results and for it to hit the market next year is lightening speed. We need a paradigm shift... A product that clearly benefits patients will be flung forward rather than encumbered.

Go Kevetrin!!!